Certified Clinical Research Associate (CCRA) Practice Test

Preparing for the Certified Clinical Research Associate (CCRA) certification exam requires more than memorizing regulations or reviewing study manuals. Success depends on understanding how Good Clinical Practice (GCP), regulatory requirements, clinical operations, participant safety, and data quality come together in real-world research settings. The exam challenges candidates to apply knowledge, evaluate complex situations, and make decisions similar to those expected of an experienced Clinical Research Associate.

Our CCRA Practice Test Questions and Answers package is designed to help you prepare with confidence. It includes 800 carefully developed multiple-choice practice questions written to reflect the style, difficulty, and decision-making expected on the CCRA certification exam. Every question is paired with a detailed explanation that reinforces key concepts, explains the correct answer, and strengthens your understanding of clinical research principles.

Instead of relying on simple fact recall, these practice tests emphasize realistic scenarios commonly encountered during clinical trial monitoring, site management, regulatory compliance, participant protection, investigational product oversight, safety reporting, documentation review, and quality management. This practical approach helps build the analytical thinking required to perform well on exam day.

Whether you are preparing for your first certification attempt or refreshing your knowledge before recertification, these practice exams provide structured practice across the major domains tested on the CCRA examination.

What’s Included

This comprehensive study resource includes:

• 800 certification-style CCRA practice questions
• Detailed answer explanations for every question
• Scenario-based clinical research cases
• Questions ranging from moderate to advanced difficulty
• Coverage of current clinical research regulations and Good Clinical Practice principles
• Exam-style multiple-choice format
• Practice designed to improve confidence, speed, and decision-making

Topics Covered

The practice questions cover the knowledge expected of professional Clinical Research Associates, including:

• Good Clinical Practice (ICH GCP)
• Clinical trial regulations
• Investigator responsibilities
• Sponsor responsibilities
• Clinical Research Associate responsibilities
• Site qualification and feasibility
• Site initiation, monitoring, and close-out visits
• Informed consent process
• Participant rights and protection
• Ethics Committee and IRB oversight
• Clinical trial documentation
• Essential documents and Trial Master File (TMF)
• Investigator Site File (ISF)
• Source documentation and ALCOA+ principles
• Electronic data capture (EDC)
• Data integrity and audit trails
• Protocol compliance
• Protocol deviations and violations
• Eligibility review and participant enrollment
• Randomization procedures
• Investigational product accountability
• Drug storage and temperature monitoring
• Device accountability and Unique Device Identifier (UDI)
• Safety reporting
• Adverse Events (AE)
• Serious Adverse Events (SAE)
• Pregnancy reporting
• Medical Monitor communication
• Data Safety Monitoring Board (DSMB)
• Independent Data Monitoring Committee (IDMC)
• Risk-Based Quality Management (RBQM)
• Risk-Based Monitoring (RBM)
• Centralized monitoring
• Key Risk Indicators (KRIs)
• Corrective and Preventive Actions (CAPA)
• Root cause analysis
• Vendor oversight
• CRO oversight
• Laboratory management
• Specimen collection and shipment
• Clinical trial inspections
• FDA inspection readiness
• Quality Management Systems (QMS)
• Database lock preparation
• Clinical trial close-out
• Regulatory documentation
• Inspection readiness and quality governance

Why Choose These CCRA Practice Tests?

Passing the CCRA certification exam requires more than reviewing definitions. Candidates must understand how regulations apply in day-to-day clinical research operations and how to respond appropriately when unexpected situations arise.

These practice exams were developed with that goal in mind. Questions focus on practical decision-making, monitoring activities, participant safety, regulatory compliance, documentation review, investigational product management, quality oversight, and inspection readiness. The detailed explanations help reinforce important concepts while explaining the reasoning behind each correct answer.

By practicing across hundreds of realistic scenarios, you can strengthen your ability to identify compliance issues, recognize potential risks, interpret clinical research regulations, and apply Good Clinical Practice principles with confidence.

Who Should Use These Practice Tests?

These practice questions are ideal for:

• Clinical Research Associates (CRAs)
• Senior CRAs
• Clinical Research Coordinators (CRCs)
• Clinical Trial Coordinators
• Clinical Trial Managers
• Clinical Project Managers
• Research Nurses
• Clinical Operations professionals
• Sponsor and CRO personnel
• Clinical research professionals preparing for CCRA certification
• Individuals seeking to improve their understanding of clinical trial monitoring and regulatory compliance

Study Smarter and Build Exam Confidence

Consistent practice is one of the most effective ways to prepare for the CCRA certification exam. Working through a large collection of realistic questions helps reinforce key concepts, improve critical thinking, and increase confidence when answering scenario-based exam questions.

The PrepPool CCRA Practice Test Questions and Answers provide extensive practice across the full clinical research lifecycle—from study startup and participant enrollment to monitoring, safety oversight, quality management, database lock, and regulatory inspection readiness. Whether you study a few questions each day or complete full-length practice sessions, this resource is designed to support steady progress toward certification success.

CCRA Sample Questions and Answers

Question 1

During a routine monitoring visit, a CCRA discovers that an investigator has enrolled a participant who failed one of the protocol’s key inclusion criteria. The participant has already completed two study visits without experiencing any adverse events. What should the CRA do FIRST?

A. Immediately remove the participant from the study.

B. Document the deviation, notify the investigator, and ensure the sponsor is informed according to study procedures.

C. Ignore the issue because no participant harm occurred.

D. Change the eligibility documentation to match the protocol.

Correct Answer: B

Detailed Explanation:

A CRA’s primary responsibility is to ensure subject safety, protocol compliance, and data integrity. When an ineligible participant is enrolled, this represents a protocol deviation regardless of whether harm has occurred. The first action is to document the finding, discuss it with the investigator, and follow sponsor procedures for reporting the deviation. The investigator—not the CRA—determines clinical management of the participant in consultation with the sponsor. Falsifying eligibility records is a serious GCP violation. Regulatory authorities expect transparent documentation and corrective actions rather than attempting to conceal protocol deviations.

Question 2

Which International Council for Harmonisation (ICH) Good Clinical Practice principle places the greatest emphasis on protecting research participants?

A. Financial accountability

B. Rights, safety, and well-being of trial participants take precedence over science and society

C. Sponsor profitability

D. Rapid database lock

Correct Answer: B

Detailed Explanation:

One of the core principles of ICH E6 Good Clinical Practice is that the rights, safety, and well-being of participants always outweigh scientific interests or societal benefits. Every decision made by investigators, sponsors, and CRAs should reflect this principle. Monitoring activities, informed consent verification, adverse event reporting, and protocol compliance all support participant protection. Financial considerations, study timelines, or publication goals must never compromise participant welfare. Regulatory agencies consistently evaluate whether participant safety remained the highest priority throughout a clinical investigation.

Question 3

Which document provides evidence that a participant voluntarily agreed to participate in a clinical trial after receiving adequate information?

A. Source worksheet

B. Investigator Brochure

C. Signed informed consent form

D. Delegation of authority log

Correct Answer: C

Detailed Explanation:

The signed informed consent form documents that the participant received adequate information about the research, understood potential risks and benefits, had an opportunity to ask questions, and voluntarily agreed to participate. The CRA verifies that the correct IRB-approved version was signed before any protocol-required procedures occurred. Although other study documents support trial conduct, none replace informed consent. Missing, outdated, or improperly executed consent forms are considered major GCP findings because participant autonomy is a fundamental ethical requirement in clinical research.

Question 4

A monitor notices that source documentation and the electronic case report form (eCRF) contain different blood pressure values for the same study visit. What is the most appropriate action?

A. Change the source document to match the eCRF.

B. Ignore the difference if it appears minor.

C. Raise a data query and verify the correct value using source documentation.

D. Delete both values.

Correct Answer: C

Detailed Explanation:

Source documents are the original records used to verify study data. When discrepancies exist between source records and the eCRF, the CRA should verify the original documentation and initiate a data query if clarification is needed. Corrections should follow established documentation procedures while maintaining an audit trail. Altering original records without justification or ignoring inconsistencies threatens data integrity. Accurate source data verification is one of the monitor’s most important responsibilities because reliable clinical conclusions depend on trustworthy study data.

Question 5

Which of the following responsibilities belongs primarily to the Institutional Review Board (IRB) or Independent Ethics Committee (IEC)?

A. Monitoring source data

B. Performing statistical analyses

C. Protecting the rights, safety, and welfare of research participants

D. Managing sponsor finances

Correct Answer: C

Detailed Explanation:

The IRB or IEC independently reviews research protocols to ensure participant rights, safety, and welfare are protected before and during the trial. Responsibilities include reviewing informed consent documents, evaluating protocol amendments, assessing participant risks, and conducting continuing review. Monitoring source data and statistical analyses are sponsor or investigator responsibilities. The CRA confirms that current IRB approvals are maintained throughout the study. Ethical oversight is an essential safeguard in clinical research and remains independent from sponsor influence.

Question 6

A site begins using a new laboratory for protocol-required testing. Which action should the CRA verify?

A. Only the laboratory invoice.

B. Documentation demonstrating laboratory qualification and required certifications before study testing begins.

C. Marketing brochures from the laboratory.

D. Staff vacation schedules.

Correct Answer: B

Detailed Explanation:

Clinical trial laboratories performing protocol-required assessments should meet applicable regulatory and accreditation requirements. The CRA verifies that laboratory certifications, normal reference ranges, equipment calibration when applicable, and qualification documentation are available before participant testing begins. Reliable laboratory results are essential for participant eligibility, safety monitoring, and efficacy analyses. Missing laboratory qualifications may jeopardize data credibility and regulatory compliance. Proper oversight ensures consistent, accurate testing throughout the study.

Question 7

Which document identifies study personnel and the specific trial responsibilities assigned to each individual?

A. Delegation of authority log

B. Monitoring visit report

C. Drug accountability log

D. Subject identification log

Correct Answer: A

Detailed Explanation:

The delegation of authority log documents which qualified individuals perform specific protocol-related tasks under the investigator’s supervision. It identifies study personnel, assigned responsibilities, start dates, and investigator authorization. During monitoring visits, the CRA verifies that only delegated, qualified staff perform study activities such as informed consent discussions, assessments, and investigational product management. An accurate delegation log demonstrates regulatory compliance and helps inspectors determine accountability throughout the clinical trial.

Question 8

A serious adverse event (SAE) occurs at a study site. What is the CRA’s primary monitoring responsibility?

A. Decide the participant’s treatment.

B. Ensure the investigator reports the SAE according to protocol, regulatory, and sponsor requirements.

C. Diagnose the participant.

D. Determine compensation.

Correct Answer: B

Detailed Explanation:

Although investigators provide clinical care, the CRA ensures that serious adverse events are documented, assessed, and reported within required timelines. Monitoring includes verifying complete documentation, confirming source records support reported information, and ensuring sponsor notification procedures are followed. Accurate SAE reporting supports ongoing safety evaluations and regulatory compliance. Failure to report serious adverse events promptly can delay safety assessments and place future participants at unnecessary risk.

Question 9

During investigational product accountability review, the drug inventory does not match dispensing records. What should the CRA do?

A. Estimate the missing quantity.

B. Investigate the discrepancy with site staff and document findings.

C. Destroy remaining medication immediately.

D. Replace the missing medication without documentation.

Correct Answer: B

Detailed Explanation:

Accurate investigational product accountability demonstrates that study medication was stored, dispensed, returned, and destroyed according to protocol. Inventory discrepancies require immediate investigation with study personnel to identify documentation errors, dispensing mistakes, or other explanations. Every discrepancy should be documented and resolved whenever possible. Estimating counts or replacing medication without records creates significant compliance concerns. Proper drug accountability protects participants and maintains study credibility.

Question 10:

Why are monitoring visit reports important?

A. They replace the clinical protocol.

B. They document monitoring activities, findings, follow-up actions, and site compliance.

C. They eliminate the need for audits.

D. They are only used for financial reimbursement.

Correct Answer: B

Detailed Explanation:

Monitoring visit reports provide written evidence that study oversight occurred according to the monitoring plan. Reports summarize site performance, protocol deviations, data quality concerns, investigational product accountability, regulatory documentation, and required follow-up actions. Sponsors rely on these reports to assess overall site compliance and identify trends requiring corrective action. Regulatory inspectors frequently review monitoring documentation to evaluate sponsor oversight. Well-prepared reports demonstrate effective monitoring throughout the trial.

Question 11

Which essential document confirms that an investigator is qualified to conduct a clinical trial?

A. Curriculum vitae and professional license

B. Hotel reservation

C. Participant diary

D. Laboratory shipping receipt

Correct Answer: A

Detailed Explanation:

ICH Good Clinical Practice requires investigators to possess appropriate education, training, and experience. Current curriculum vitae and professional licenses demonstrate qualifications and should be maintained in the Trial Master File and investigator site file. CRAs verify these documents before study initiation and periodically update them as required. Investigator qualifications help ensure participants receive competent medical oversight and that study procedures are performed according to regulatory expectations.

Question 12

A participant decides to withdraw consent during the study. Which statement is correct?

A. The participant must continue until study completion.

B. Withdrawal is allowed at any time without penalty or loss of entitled benefits.

C. Withdrawal requires sponsor approval.

D. Withdrawal automatically invalidates all previously collected data.

Correct Answer: B

Detailed Explanation:

Respect for participant autonomy is a fundamental ethical principle in clinical research. Participants may withdraw consent at any time without coercion, penalty, or loss of benefits to which they are otherwise entitled. The investigator should document the withdrawal, determine whether additional safety follow-up is appropriate, and follow protocol procedures regarding previously collected data. The CRA verifies proper documentation and compliance with regulatory requirements. Participant rights remain protected throughout the entire research process.

Question 13

Which monitoring activity best supports data integrity?

A. Source data verification of critical study variables

B. Increasing participant compensation

C. Shortening follow-up visits

D. Reducing protocol documentation

Correct Answer: A

Detailed Explanation:

Source data verification (SDV) compares information recorded in the case report form with original source documents to confirm accuracy, completeness, and consistency. Modern risk-based monitoring focuses SDV on critical data affecting participant safety and primary study endpoints. Effective SDV identifies transcription errors, missing documentation, and inconsistencies before database lock. High-quality data strengthens the scientific validity of trial results and supports regulatory acceptance of study findings.

Question 14

What is the primary purpose of a Corrective and Preventive Action (CAPA) plan following repeated protocol deviations?

A. Increase enrollment numbers.

B. Identify root causes, correct current issues, and prevent recurrence.

C. Reduce monitoring visits.

D. Eliminate documentation requirements.

Correct Answer: B

Detailed Explanation:

CAPA is a structured quality management process used after identifying significant or recurring compliance issues. Corrective actions resolve existing problems, while preventive actions reduce the likelihood of future recurrence. Effective CAPA begins with root cause analysis rather than simply addressing symptoms. The CRA evaluates whether implemented actions are appropriate, documented, and effective during subsequent monitoring visits. Regulatory agencies expect sponsors and investigators to use CAPA as part of a robust quality management system.

Question 15

Risk-based monitoring (RBM) primarily aims to:

A. Monitor every data point equally.

B. Focus monitoring resources on processes and data that are critical to participant safety and study quality.

C. Eliminate all on-site monitoring.

D. Reduce regulatory oversight.

Correct Answer: B

Detailed Explanation:

Risk-based monitoring is recommended by current ICH E6(R3) principles and modern regulatory expectations. Rather than verifying every piece of study data, RBM prioritizes monitoring activities that have the greatest impact on participant safety, primary endpoints, informed consent, investigational product management, and protocol compliance. Centralized monitoring, statistical data review, and targeted on-site visits improve efficiency while maintaining study quality. A successful RBM strategy uses quality risk management to allocate monitoring resources where they provide the greatest benefit to trial integrity and participant protection.

Question 16.

A participant was enrolled based on a local laboratory creatinine result that met protocol eligibility requirements. Three days later, the central laboratory reported that the participant did not actually meet the renal function criterion.

What is the CRA’s BEST next step?

A. Immediately withdraw the participant from the study.

B. Document the finding, notify the investigator, and ensure the sponsor is informed according to the protocol while the investigator determines appropriate clinical management.

C. Ignore the central laboratory result because enrollment already occurred.

D. Ask the laboratory to repeat the result until it meets eligibility.

Correct Answer: B

Detailed Explanation:

When discrepancies arise between local and central laboratory results, the CRA should not independently decide whether a participant remains in the study. The finding must be documented, discussed with the investigator, and reported to the sponsor according to protocol requirements. The investigator evaluates participant safety and determines whether continued participation is appropriate. Accurate documentation is essential because enrollment of potentially ineligible participants may affect both safety and study validity. Regulatory inspections often review how sponsors and investigators manage eligibility discrepancies and whether protocol-required reporting procedures were followed.

Question 17.

While reviewing medical records, you discover that a participant’s concomitant medication was documented in the hospital chart but never entered into the electronic case report form.

What should the CRA do?

A. Enter the medication into the eCRF personally.

B. Issue a data query requesting the site to update the eCRF using verified source documentation.

C. Ignore the omission because the medication was unrelated to the study.

D. Delete the medication from the medical record.

Correct Answer: B

Detailed Explanation:

Source documents are considered the primary evidence for study data. If information documented in the medical record has not been transferred to the eCRF, the CRA should issue a query so authorized site personnel can update the study database. CRAs monitor and verify data but should not independently modify study records. Missing concomitant medications may influence safety assessments, efficacy analyses, or protocol compliance. Maintaining consistency between source records and the eCRF strengthens data integrity and supports reliable clinical trial results.

Question 18.

An FDA inspector asks how the sponsor ensured adequate monitoring throughout the study.

Which documentation provides the strongest evidence?

A. Monitoring visit reports and the approved monitoring plan

B. Site payment records

C. Participant appointment schedules

D. Recruitment logs

Correct Answer: A

Detailed Explanation:

Monitoring visit reports document the activities performed, observations made, protocol deviations identified, corrective actions recommended, and follow-up completed during study oversight. Together with the sponsor’s monitoring plan, these reports demonstrate that monitoring was systematic, risk-based, and consistent with Good Clinical Practice. Inspectors frequently review monitoring documentation to determine whether sponsors fulfilled their oversight responsibilities. Complete, timely monitoring reports also help identify recurring quality issues across study sites and support continuous improvement throughout the clinical trial.

Question 19. 

During a monitoring visit, you discover that one participant missed a required Week 8 ECG because the equipment was unavailable.

How should this event be classified?

A. Protocol deviation

B. Serious adverse event

C. Source document error

D. Monitoring visit deficiency only

Correct Answer: A

Detailed Explanation:

Failure to complete a protocol-required assessment is generally considered a protocol deviation because the study was not conducted exactly as described in the approved protocol. The CRA should verify documentation explaining why the ECG was missed, determine whether participant safety was affected, and ensure sponsor notification if required. The investigator should also evaluate whether the missed assessment compromises participant management or study endpoints. Proper documentation and corrective actions help reduce the likelihood of similar deviations occurring in the future.

Question 20.

A participant asks whether declining an optional genetic substudy will affect participation in the main clinical trial.

What is the correct response?

A. Yes, participation in both studies is mandatory.

B. No. Declining optional research should not affect participation in the primary study if the protocol specifies that the substudy is voluntary.

C. The CRA should decide whether the participant remains eligible.

D. The participant must ask the sponsor directly.

Correct Answer: B

Detailed Explanation:

Optional research components, such as genetic or pharmacogenomic substudies, require separate voluntary consent when specified by the protocol. Participants have the right to decline optional procedures without affecting their participation in the primary study. Respecting participant autonomy is a core ethical principle under Good Clinical Practice. The CRA should verify that consent documentation clearly distinguishes mandatory study procedures from optional research activities and that participants are not subjected to coercion or undue influence during the consent process.

Question 21.

During a routine monitoring visit, you identify the following:

• All informed consent forms are complete and current.
• Drug accountability records reconcile perfectly.
• A protocol amendment requiring renal function review before dosing has been in effect for one month.
• Two participants received investigational product before laboratory review, although laboratory results later met protocol requirements.
• Monitoring reports from the previous visit recommended implementing a laboratory review checklist, but the recommendation was never adopted.

Which finding presents the greatest overall regulatory concern?

A. Drug accountability is accurate.

B. Failure to implement previously recommended corrective actions, resulting in repeated protocol noncompliance affecting participant safety.

C. Current informed consent forms.

D. Laboratory results ultimately met protocol requirements.

Correct Answer: B

Detailed Explanation:

Although both participants ultimately met renal function requirements, investigational product was administered before protocol-mandated laboratory review, violating established safety procedures. More importantly, the same operational weakness had already been identified during a previous monitoring visit, and the recommended corrective action—a laboratory review checklist—was never implemented. This demonstrates ineffective site oversight, inadequate CAPA implementation, and a failure to address known risks. Regulatory inspectors pay particular attention to repeated deficiencies because they indicate that the site’s quality management system is not effectively preventing recurrence. The CRA should immediately verify participant safety, ensure sponsor notification according to protocol, conduct a thorough root cause analysis, and confirm implementation of strengthened corrective and preventive measures before additional participants are treated.

Question 22.

A global Phase III hematology study uses AI-assisted centralized monitoring, wearable hemoglobin monitoring devices, electronic informed consent, cloud-hosted electronic source records, decentralized laboratory collection, home infusion services, and direct-to-patient investigational product shipments.

During monitoring, you identify the following:

• Drug accountability is fully reconciled.
• Essential documents remain current.
• Wearable devices continue transmitting participant data.
• AI-generated alerts identify rapidly declining hemoglobin values.
• Previous CAPA required investigator review of critical alerts within 60 minutes, automatic escalation after missed acknowledgments, monthly cybersecurity monitoring, quarterly cloud infrastructure audits, annual AI model validation, semiannual disaster recovery exercises, and quarterly executive Quality Management reviews.
• Investigator response times declined after staffing reductions.
• Automatic escalation failed following an undocumented software configuration update.
• Monthly cybersecurity monitoring has not been performed for four months.
• Cloud infrastructure audits are overdue.
• AI model validation was not completed following the latest software release.
• Disaster recovery exercises were postponed without documented justification.
• Executive quality review meetings have not occurred for two consecutive quarters.
• Four participants experienced delayed clinical intervention after critical hemoglobin alerts.

Which finding represents the greatest overall regulatory concern?

A. Accurate investigational product accountability.

B. Failure to maintain integrated oversight of AI-assisted monitoring, computerized systems, cybersecurity, infrastructure governance, disaster recovery, vendor oversight, investigator responsiveness, and executive quality management, resulting in delayed participant safety interventions.

C. Complete essential documentation.

D. Successful wearable device performance.

Correct Answer: B

Detailed Explanation:

This scenario demonstrates a systemic breakdown of the sponsor’s Quality Management System. While the technology continued to collect data and detect clinically significant abnormalities, the organizational controls required to ensure timely participant protection failed across multiple critical domains. Investigator responsiveness, automated escalation, cybersecurity oversight, infrastructure governance, AI lifecycle management, disaster recovery preparedness, vendor oversight, and executive quality governance all deteriorated simultaneously. These failures delayed medical intervention for participants with severe hematologic abnormalities, directly affecting participant safety. Under ICH E6(R3), sponsors remain responsible for ensuring that technology, vendors, computerized systems, investigators, and quality governance operate as an integrated framework throughout the study lifecycle. The CRA should immediately evaluate participant impact, escalate the findings through sponsor governance channels, investigate the undocumented software configuration change, restore automated escalation pathways, complete overdue cybersecurity and disaster recovery activities, revalidate the AI system, resume infrastructure audits and executive quality reviews, conduct a comprehensive root cause analysis, and verify long-term CAPA effectiveness using objective quality metrics. This integrated, judgment-based scenario closely mirrors the complexity expected on the 2026 Certified Clinical Research Associate (CCRA) examination.